DarioHealth Corp. filed an 8-K press release on November 4, 2026, announcing the appointment of John R. Palumbo as Chairman of the Board of Directors, effective November 3, 2026, succeeding Yoav Shaked who will remain a director.

Key Highlights

  • New Chairman: John R. Palumbo was appointed Chairman of the Board effective November 3, 2026, having first joined the Board in April 2026.
  • Predecessor remains: Yoav Shaked, who served as Chairman since 2018, will continue as a director of the company.
  • Earnings call appearance: Mr. Palumbo is scheduled to join DarioHealth's third quarter 2026 earnings conference call on November 12, 2026.
  • Platform metrics cited: According to the filing, more than 80% of contracted and late-stage annual recurring revenue is multi-condition, and the company has more than 180 signed enterprise accounts including more than a dozen health plans.
  • Clinical evidence cited: The filing references $5,077 in annual savings per user and 23.5% fewer inpatient discharges among members with type 2 diabetes, plus an independent Aon review of 17 studies supporting a 2.5% to 7.2% in-year reduction in total healthcare costs.
  • Data scale: The company disclosed more than 13 billion proprietary data points and more than 100 scientific studies supporting its platform.
  • Channel partner reliance: According to the filing, approximately 75% of new accounts come through channel partners.

Palumbo Appointment and DarioHealth's Strategic Context

DarioHealth Corp. (NASDAQ:DRIO) disclosed the appointment of John R. Palumbo as Chairman of its Board of Directors, effective November 3, 2026. Mr. Palumbo, who joined the Board in April 2026, brings what the filing describes as more than 40 years of healthcare operating experience spanning early-stage ventures and Fortune 100 enterprises. His background, as stated in the filing, includes senior leadership at AmerisourceBergen Corporation (now Cencora, Inc.), where he led the provider business unit and expanded consulting and technology capabilities into what the filing calls "a multibillion-dollar platform serving health systems nationwide." He also served as Chief Operating Officer of Allscripts Healthcare Solutions, Inc. (now Veradigm, Inc.) and held leadership positions at Shared Medical Systems Corporation (now Oracle).

The filing frames the appointment in the context of what DarioHealth characterizes as a convergence of consumer-directed and payer-funded healthcare. The company specifically references the CMS ACCESS Model, launched in July 2026, which the filing states "now pays for outcomes in hypertension, diabetes, musculoskeletal conditions and depression," conditions the company says align with its existing chronic care management offerings. CEO Erez Raphael is quoted in the filing stating: "John has spent his career inside the payer, provider and health services organizations that are shaping where this market is going, and he has worked hand-in-hand with our team since April."

Outgoing Chairman Yoav Shaked, who held the role since 2018, is quoted in the filing saying: "John is the right leader for the Board's next chapter, and I look forward to continuing to support the Company as a director." Mr. Palumbo currently serves on the boards of PM Pediatrics Management Group, LLC, Lucid Diagnostics Inc., ivWatch, LLC, and Qless, Inc., and chairs the advisory board of Brado Cuneo Nollau, LLC, according to the filing. The filing contains forward-looking statements that the company notes are subject to its cautionary language and applicable risk factors disclosed with the SEC.

What Was Disclosed

DarioHealth announced the appointment of John R. Palumbo as Board Chairman effective November 3, 2026, replacing Yoav Shaked who remains a director. The filing also cited platform metrics, clinical evidence figures, and noted Mr. Palumbo's planned participation in the November 12, 2026 earnings call.